Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions. [PDF]
Allergy, 2022 Bruton's tyrosine kinase (BTK), a member of the Tec kinase family, is critically involved in a range of immunological pathways. The clinical application of BTK inhibitors for B‐cell malignancies has proven successful, and there is strong rationale for ...
Mendes-Bastos P +6 more
europepmc +8 more sources
Bruton's Tyrosine Kinase Inhibitors: Recent Updates. [PDF]
Int J Mol SciBruton’s tyrosine kinase (BTK) inhibitors have revolutionized the landscape for the treatment of hematological malignancies, solid tumors, and, recently, autoimmune disorders.
Fares A +5 more
europepmc +4 more sources
Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis. [PDF]
Curr Neurol Neurosci Rep, 2022 Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) with a chronic and often progressive disease course. The current disease-modifying treatments (DMTs) limit disease progression primarily by dampening immune cell ...
Schneider R, Oh J.
europepmc +4 more sources
Mutations of Bruton's tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia [PDF]
Brazilian Journal of Medical and Biological Research, 2010 Mutations in Bruton's tyrosine kinase (BTK) gene are responsible for X-linked agammaglobulinemia (XLA), which is characterized by recurrent bacterial infections, profound hypogammaglobulinemia, and decreased numbers of mature B cells in peripheral blood.
V.D. Ramalho +4 more
doaj +6 more sources
Efficacy and safety of Bruton's tyrosine kinase inhibitors in the treatment of pemphigus: A comprehensive literature review and future perspective [PDF]
Heliyon, 2023 Bruton's tyrosine kinase (BTK) is a protein involved in B-cell-receptor signaling and B-cell proliferation. The pathophysiology of several autoimmune diseases, such as pemphigus disorder, relies on the BTK signaling pathway.
Yekta Ghane +4 more
doaj +2 more sources
A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis. [PDF]
Ther Adv Neurol DisordBruton’s tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic cells, microglia and macrophages, integral effectors of ...
Airas L +8 more
europepmc +2 more sources
A novel Bruton's tyrosine kinase inhibitor JDB175 shows potent efficacy to suppress central nervous system lymphoma [PDF]
MedComm, 2023 Patients with central nervous system (CNS) lymphoma face limited treatment options and poor treatment outcomes, emphasizing the urgent need for effective therapeutic strategies.
Yong Xia, Xue Li, Ning Jiang, Xiawei Wei
doaj +2 more sources
Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies [PDF]
Scientific Reports, 2023 Bruton's tyrosine kinase (BTK) is a non-receptor protein kinase that plays a crucial role in various biological processes, including immune system function and cancer development.
Mohammed Alrouji +8 more
doaj +2 more sources
Non-Covalent Bruton's Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia. [PDF]
Cancers (Basel), 2023 Simple Summary Non-covalent Bruton’s tyrosine kinase inhibitors (ncBTKi) are being investigated for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL).
Montoya S, Thompson MC.
europepmc +2 more sources
Genomics Data, 2016 Mast cells play critical roles during immune responses to the bacterial endotoxin lipopolysaccharide (LPS) that can lead to fatal septic hypothermia [1–3].
Weishan Huang, Avery August
doaj +2 more sources